AIM Vaccine expects revenue of 1.25 billion to 1.3 billion yuan in 2024
March 20, 2025
Source: drugdu
54
AIM Vaccine (06660) issued an announcement that it is expected that the Group's unaudited revenue will be between 1.25 billion and 1.3 billion yuan during the reporting period ending December 31, 2024, an increase of 60 million to 110 million yuan from 1.19 billion yuan in the previous year, an increase of 5% to 9%.
At the same time, the unaudited net loss is expected to be between 250 million and 290 million yuan, a significant reduction from the net loss of 1.95 billion yuan in the previous year, with a reduction of 85% to 87%.
The announcement pointed out that the main reason for the increase in revenue was the company's sales growth of hepatitis B vaccines, while the reduction in comprehensive net losses was due to the reduction in the amount of large asset impairment losses and the increase in revenue this year.
https://finance.eastmoney.com/a/202503173347407027.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- 6 domestic ADCs successfully go global April 3, 2025
- Medical equipment giant begins layoffs and factory closures April 3, 2025
- Cultivate “Innovation Skills” and Cultivate “Conscience Seedlings” April 3, 2025
- Zhifei Biotech’s adjuvanted trivalent influenza vaccine has obtained clinical trial approval, which is expected to further enrich the company’s virus vaccine varieties April 3, 2025
- Under the vaccine price war, the performance of the leading influenza vaccine company Hualan Vaccine in 2024 has stalled April 3, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
